The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives

BACKGROUND: Necitumumab (Neci) was the first biologic approved by the FDA for use in combination with gemcitabine and cisplatin (Neci + GCis) in first-line treatment of metastatic squamous non-small cell lung cancer (msqNSCLC). The potential financial impact on a health plan of adding Neci + GCis to...

Descripción completa

Detalles Bibliográficos
Autores principales: Bly, Christopher A., Molife, Cliff, Brown, Jacqueline, Tawney, Mahesh K., Carter, Gebra Cuyun, Cinfio, Frank N., Klein, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397628/
https://www.ncbi.nlm.nih.gov/pubmed/29799326
http://dx.doi.org/10.18553/jmcp.2018.24.6.534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397628/
https://www.ncbi.nlm.nih.gov/pubmed/29799326
http://dx.doi.org/10.18553/jmcp.2018.24.6.534

Ejemplares similares